Alnylam Pharmaceuticals (NASDAQ:ALNY) Hits New 1-Year Low Following Analyst Downgrade

Alnylam Pharmaceuticals logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Alnylam Pharmaceuticals fell to a new 52-week low of $149.18 after Rodman & Renshaw downgraded the stock to neutral; it had closed at $156.50 the previous session.
  • Several analysts cut their price targets, though MarketBeat’s consensus remained “Moderate Buy”, with an average target of $287.57.
  • The company reported quarterly earnings of $16.26 per share, well above the $1.66 consensus estimate, and revenue of $1.46 billion, up 16.7% year over year.
  • Interested in Alnylam Pharmaceuticals? Here are five stocks we like better.

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Get Free Report)'s share price reached a new 52-week low during trading on Wednesday after Rodman & Renshaw downgraded the stock to a neutral rating. The stock traded as low as $149.18 and last traded at $149.3190, with a volume of 1,250,917 shares. The stock had previously closed at $156.50.

Other analysts have also issued reports about the stock. Oppenheimer reduced their price target on shares of Alnylam Pharmaceuticals from $350.00 to $320.00 and set an "outperform" rating for the company in a research note on Friday, October 30th. Morgan Stanley lowered their price objective on shares of Alnylam Pharmaceuticals from $300.00 to $240.00 and set an "equal weight" rating on the stock in a research report on Friday, October 30th. Bank of America reaffirmed a "buy" rating and issued a $287.00 target price (down from $460.00) on shares of Alnylam Pharmaceuticals in a research report on Friday, October 30th. UBS Group decreased their target price on shares of Alnylam Pharmaceuticals from $550.00 to $329.00 and set a "buy" rating for the company in a research note on Friday, October 30th. Finally, JPMorgan Chase & Co. set a $254.00 price target on Alnylam Pharmaceuticals in a report on Wednesday. One analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and eleven have issued a Hold rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $287.57.

Read Our Latest Analysis on Alnylam Pharmaceuticals

Insider Transactions at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, EVP Bryan Supran sold 1,758 shares of the stock in a transaction that occurred on Friday, October 2nd. The shares were sold at an average price of $226.88, for a total value of $398,855.04. Following the transaction, the executive vice president directly owned 12,807 shares in the company, valued at approximately $2,905,652.16. This trade represents a 12.07% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Company insiders own 0.86% of the company's stock.

Institutional Trading of Alnylam Pharmaceuticals

Several hedge funds have recently bought and sold shares of ALNY. Bank of Nova Scotia raised its position in shares of Alnylam Pharmaceuticals by 0.6% during the 1st quarter. Bank of Nova Scotia now owns 7,798 shares of the biopharmaceutical company's stock worth $2,580,000 after purchasing an additional 49 shares during the last quarter. SBI Securities Co. Ltd. grew its holdings in Alnylam Pharmaceuticals by 27.8% during the 3rd quarter. SBI Securities Co. Ltd. now owns 225 shares of the biopharmaceutical company's stock valued at $56,000 after buying an additional 49 shares during the last quarter. Prestige Wealth Management Group LLC increased its position in Alnylam Pharmaceuticals by 30.6% during the first quarter. Prestige Wealth Management Group LLC now owns 226 shares of the biopharmaceutical company's stock worth $75,000 after buying an additional 53 shares in the last quarter. Fortitude Family Office LLC increased its position in Alnylam Pharmaceuticals by 10.5% during the third quarter. Fortitude Family Office LLC now owns 578 shares of the biopharmaceutical company's stock worth $143,000 after buying an additional 55 shares in the last quarter. Finally, Glenmede Trust Co. NA raised its holdings in shares of Alnylam Pharmaceuticals by 8.3% in the first quarter. Glenmede Trust Co. NA now owns 731 shares of the biopharmaceutical company's stock worth $242,000 after acquiring an additional 56 shares during the last quarter. Institutional investors own 92.97% of the company's stock.

Alnylam Pharmaceuticals Stock Performance

The company has a quick ratio of 2.43, a current ratio of 2.48 and a debt-to-equity ratio of 0.18. The stock has a fifty day moving average price of $215.05 and a two-hundred day moving average price of $274.10. The company has a market capitalization of $19.92 billion, a price-to-earnings ratio of 7.74 and a beta of 0.42.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last posted its quarterly earnings data on Thursday, October 29th. The biopharmaceutical company reported $16.26 EPS for the quarter, topping analysts' consensus estimates of $1.66 by $14.60. The firm had revenue of $1.46 billion during the quarter, compared to analysts' expectations of $1.43 billion. Alnylam Pharmaceuticals had a return on equity of 155.33% and a net margin of 52.85%. The firm's quarterly revenue was up 16.7% compared to the same quarter last year. During the same quarter last year, the business posted $2.90 EPS. As a group, analysts forecast that Alnylam Pharmaceuticals, Inc. will post 6.85 EPS for the current fiscal year.

Alnylam Pharmaceuticals Company Profile

(Get Free Report)

Alnylam Pharmaceuticals is a biopharmaceutical company focused on discovering, developing and commercializing medicines based on RNA interference (RNAi), a biological process that can reduce the production of specific disease-causing proteins. Founded in 2002 and headquartered in Cambridge, Massachusetts, the company helped advance RNAi from a scientific discovery into a therapeutic approach. Its marketed medicines include ONPATTRO (patisiran) and AMVUTTRA (vutrisiran) for hereditary transthyretin-mediated amyloidosis, GIVLAARI (givosiran) for acute hepatic porphyria, and OXLUMO (lumasiran) for primary hyperoxaluria type 1.

Featured Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Alnylam Pharmaceuticals Right Now?

Before you consider Alnylam Pharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alnylam Pharmaceuticals wasn't on the list.

While Alnylam Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Best Space Stocks to Own in 2026 Cover

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines